Tag: ODAC
Advisory Committee Votes in Favor of Positive Benefit/Risk Profile for Belantamab...
The U.S. Food and Drug Administration's (FDA) Oncologic Drugs Advisory Committee (ODAC) has voted 12-0 in favor of positive benefit/risk profile for belantamab mafodotin...